Back to Awarded Treatment Trials


Awarded Trial: 02T-175

Grant ID

02T-175

Illness

Schizophrenia, prodromal stage

Primary Drug/Intervention

Glycine

Primary Dosage

0.8g/d/kg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Woods

Sample Size

10

Duration of Study Period for Each Subject

8 weeks

Outcome Measurements

Scale of Prodromal Symptoms, YMS, Cognitive Battery

Results

Ten patients were enrolled and seven completed 8 weeks of the treatment. Three of seven patients met early remission criteria while on glycine. Ratings for positive symptoms showed the best improvement.

Publication

N/A

Link

N/A

PI Name

Scott Woods

Degree

MD

Center

School of Medicine

Institution

Yale University

Address

CMHC, 34 Park Street, Room B38

City or Town

New Haven

State or Province

CT

Zip or Postal Code

6519

Country

USA

Email Address

scott.woods@yale.edu